(Illustration)
Photo: Shutterstock
Mazor Robotics eyes $15M financial round
Israeli spine surgery robotic guidance systems' manufacturer also plans $7.5 million NYSE IPO
Mazor Robotics, which develops innovator in spine surgery robotic guidance systems aims to raise about $15 million from private and institutional investors.
Mazor's technologies are FDA and CE approved and are used in the United States and Europe. The company hopes much of the capital will be raised through several top US pharmaceutical companies.
Breakthrough
Sarit Rosenblum
Vladislav Zaitsev was suffering from severe jaw infection; with doctors at loss, it was decided to bring in engineers who used missile technology to construct brand new jaw
The Israeli company's flagship product is the Renaissance system – a next-generation robotic surgical guidance system used for spine surgeries.
Once the funds are raised, Mazor plans to list in the New York Stock Exchange with an IPO of shares worth $7.5 million and an additional $7.5 million in options.
"Our vision is to become a leading player in the field of robotic medicine," Mazor CEO Uri Hadomi told Yedioth Ahronoth.
"We believe that our rich experience and knowledge will serve as an incentive for investors to support our innovativeness and will help Mazor meet its goals in the US market, as well as in the Asian and European markets."
